Suppr超能文献

套细胞淋巴瘤外周血中低绝对CD4 T细胞计数的不良预后影响

Negative prognostic impact of low absolute CD4 T cell counts in peripheral blood in mantle cell lymphoma.

作者信息

Zhang Xin-Yu, Xu Ji, Zhu Hua-Yuan, Wang Yan, Wang Li, Fan Lei, Wu Yu-Jie, Li Jian-Yong, Xu Wei

机构信息

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.

Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.

出版信息

Cancer Sci. 2016 Oct;107(10):1471-1476. doi: 10.1111/cas.13020. Epub 2016 Sep 14.

Abstract

Tumor microenvironment and host immunity are closely related to outcome in patients with mantle cell lymphoma (MCL). However, few researchers have focused on the prognostic value of peripheral blood lymphocyte subsets counts. The purpose of this study was to investigate the prognostic value of lymphocyte subsets and absolute monocyte counts. Sixty-eight patients were analyzed retrospectively. Absolute CD4 T cell counts (ACD4C), CD8 T cell counts, nature killer cell counts, and CD4/CD8 ratios were assessed by peripheral blood flow cytometry and correlated with clinical parameters and long-term outcomes. The median follow-up for all patients was 21 months and the median survival time was 44 months. The overall survival (OS) rate at 1, 3, and 5 years was 80%, 51%, and 41%, respectively. In our cohort, high absolute monocyte count, and low ACD4C and CD4/CD8 ratio were associated with unfavorable OS (P = 0.029, P = 0.027, and P = 0.045, respectively) by univariate analysis. Multivariate analysis indicated that low ACD4C was a significant predictor of unfavorable OS (P = 0.004) independent of the simplified MCL International Prognostic Index (P = 0.048) in patients treated with or without rituximab (P = 0.011). Low CD4 T cell counts proved to be a significant predictor of unfavorable OS in patients with MCL.

摘要

肿瘤微环境和宿主免疫与套细胞淋巴瘤(MCL)患者的预后密切相关。然而,很少有研究人员关注外周血淋巴细胞亚群计数的预后价值。本研究的目的是探讨淋巴细胞亚群和绝对单核细胞计数的预后价值。对68例患者进行回顾性分析。通过外周血流式细胞术评估绝对CD4 T细胞计数(ACD4C)、CD8 T细胞计数、自然杀伤细胞计数和CD4/CD8比值,并将其与临床参数和长期预后相关联。所有患者的中位随访时间为21个月,中位生存时间为44个月。1年、3年和5年的总生存率(OS)分别为80%、51%和41%。在我们的队列中,单因素分析显示,高绝对单核细胞计数、低ACD4C和低CD4/CD8比值与不良OS相关(P分别为0.029、0.027和0.045)。多因素分析表明,在接受或未接受利妥昔单抗治疗的患者中(P = 0.011),低ACD4C是不良OS的显著预测因素(P = 0.004),独立于简化的MCL国际预后指数(P = 0.048)。低CD4 T细胞计数被证明是MCL患者不良OS的显著预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2a/5084668/7f9412aee634/CAS-107-1471-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验